Rare Disease 2 —
Training activity: 13

Details

Review referrals; analyse, interpret and report the results of diagnostic, presymptomatic and carrier testing for FMR1 related conditions to include:

• Fragile X syndrome
• Premature Ovarian Failure (POF)
• Fragile X- associated tremor/ataxia syndrome

Type

Developmental training activity (DTA)

Evidence requirements

Evidence the activity has been undertaken by the trainee​.

Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.

An action plan to implement learning and/or to address skills or knowledge gaps identified.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

What are the intended outcomes of the training activity?

• How does performing the targeted analysis and interpreting clinical significance lead to a safe and high-quality report?
• What specific technical knowledge do you need regarding triplet repeat PCR or fragment analysis for sizing the CGG expansion in the FMR1 gene?
• Have you reviewed the established repeat ranges (normal, intermediate, premutation, and full mutation) and the relevant guidelines for reporting these distinct clinical outcomes?
• What technical metrics (e.g., stutter peaks, internal standards, or assay sensitivity for large expansions) must you monitor to ensure the service is safe?
• How will you use your findings to inform the clinical management of patients with different presentations, such as Fragile X syndrome, POF, or FXTAS?

What do you anticipate you will learn from the experience?

• What do you hope to gain regarding the genetic basis of these conditions, such as the mechanism of anticipation or the difference between premutation and full mutation alleles?
• How will you learn to correlate specific repeat sizes with the varied clinical presentations of Fragile X syndrome, Premature Ovarian Failure, and FXTAS?
• What is your current understanding of the inheritance patterns of FMR1 expansions and their impact on different family members?

What actions will you take in preparation for the experience?

• Will you review the laboratory’s Standard Operating Procedures (SOPs) and relevant literature on FMR1 testing?
• Have you planned to discuss previous examples or complex cases to understand how to handle diagnostic versus presymptomatic pathways?
• What potential difficulties do you anticipate, such as ambiguous repeat numbers, poor data quality, or the need to integrate complex family histories into your interpretation?
• How do you feel about the responsibility of reporting results for conditions like Fragile X syndrome, which have significant reproductive and familial implications?
• In what situations (e.g., encountering a borderline result or an unusual expansion pattern) will you seek immediate advice from a senior scientist to ensure you are practicing safely?

In action

What are you doing?

• How are you currently approaching the analysis of FMR1 triplet repeat assay data (e.g., PCR-based fragment analysis), and why have you chosen this particular sequence of steps?
• What decisions are you making right now to determine if repeat numbers fall within the normal, intermediate, premutation, or full mutation range?
• Which aspects of your practice feel bottom-up or intuitive, and which require conscious effort or constant reference to disorder-specific guidelines?

How are you progressing with the activity?

• How effective are your current strategies in identifying potentially pathogenic expansions or unusual repeat patterns associated with FMR1?
• How are you managing real-time challenges such as ambiguous repeat sizes, technical artefacts like stutter peaks, or difficulties in correlating repeat size with the clinical presentation (e.g., POF)?
• What are you learning from the data as it unfolds regarding unexpected findings or emerging patterns that require further investigation, such as unusual repeat configurations?

How are you adapting to the situation?

• Which alternative strategies, such as reviewing raw electropherogram data or consulting different bioinformatic tools, are you considering if the initial assessment is unclear?
• How are you identifying the point where you need immediate support or guidance regarding clinical significance, particularly when distinguishing between different FMR1-related phenotypes?
• How are you ensuring that your interpretation remains strictly within your professional scope of practice and aligns with established laboratory protocols?
• How are you adapting your interpretation to carefully account for the clinical information provided in the referral, such as symptoms of ataxia for FXTAS or family history of intellectual disability for Fragile X?

On action

What happened?

• How would you summarise the cases you reviewed and the specific assays performed (e.g., PCR-based fragment analysis for CGG repeats)?
• What was the range of results you encountered, and did you identify samples across the normal, intermediate, premutation, and full mutation ranges?
• Did you notice any unusual findings, such as significant somatic mosaicism or technical artefacts like stutter peaks that complicated sizing?
• How did you feel when managing these results, especially given the significant reproductive and familial implications for the patients involved?

How has this experience contributed to your developing practice?

• How has your ability to distinguish between repeat ranges and understand their distinct clinical implications (e.g., Fragile X, POF, and FXTAS) improved?
• In what ways have you become more proficient in using specific analysis tools and adhering to best practice guidelines for triplet repeat nomenclature?
• How did you successfully manage challenging or ambiguous results, such as identifying a ‘faint’ full mutation band in a female or resolving discrepancies with clinical referral data?
• How did your ‘reflection-in-action’ (e.g., adjusting bioinformatic filters or reviewing raw electropherograms) directly influence the final interpretation?
• How does mastering this specific FMR1 expertise contribute to your readiness for post-programme practice as a Clinical Scientist?

What will you take from the experience moving forward?

• What specific areas, such as differentiating repeat expansions or reporting borderline results near the premutation threshold, require further practice?
• How will you incorporate a more systematic approach (e.g., reviewing QC metrics or detailed family histories) into your routine work for FMR1 referrals?
• Which ‘next steps’—including reviewing national/ACMG guidelines or discussing complex cases with senior clinical geneticists – will you take to consolidate this learning?
• What additional support or resources, such as specialised triplet repeat databases or expert mentorship for complex reporting scenarios, have you identified as necessary for your ongoing development?

Beyond action

Have you revisited the experiences?

• How has your understanding of the different FMR1 repeat ranges (normal, intermediate, premutation, and full mutation) evolved or deepened since your initial analyses?
• Which specific strategies used by senior scientists for managing complex or borderline results have you successfully assimilated into your routine work?
• In what ways has discussing challenging FMR1 cases—such as those involving low-level mosaicism—with peers and senior colleagues transformed your perspective?
• What overarching themes regarding the challenges and clinical implications of non-Mendelian inheritance have you identified through a wider review of your reflections across the Adult or Paediatric Genomics modules?

How have these experiences impacted your current practice?

• How has mastering FMR1 testing served as a foundational step in developing your broader high-level skills in interpretive report writing, clinical reasoning, and quality control?
• To what extent are you now more adept at identifying technical artefacts or reviewing Standard Operating Procedures (SOPs) with a more critical eye based on your experience with these assays?
• How has your sensitivity to the nuances of carrier status and the distinct clinical implications of pre-mutation alleles (e.g., risks of POF or FXTAS) versus full mutations developed in your current practice?
• How is this accumulated learning supporting your preparation for ‘in-person’ assessments, such as a Case-based Discussion (CBD) on ethical complexities or an Observed Communication Event (OCE)?

How might these contribute towards your future practice?

• Which solidified skills, such as genotype-phenotype correlation and navigating complex variant interpretation guidelines, do you recognise as most vital for your future career as a Clinical Scientist?
• Which clear next steps for continued development – including attending specialist workshops, reviewing updated national guidelines, or seeking mentorship for sensitive communication – will you take to stay at the forefront of this field?
• How has this experience underscored the necessity of a patient-centred approach, particularly regarding the significant reproductive and familial implications inherent in FMR1-related conditions?

Relevant learning outcomes

#	Outcome
# 1	Outcome Review referrals for patients referred for rare disease genomic testing.
# 2	Outcome Analyse, interpret and report results for diagnostic, presymptomatic and familial/carrier rare disease genomic testing.
# 3	Outcome Perform targeted analysis, whole genome analysis, and chromosomal analysis for patients referred for rare disease genomic testing.
# 4	Outcome Interpret genomic variants to investigate their clinical significance for patients referred for rare disease genomic testing.
# 7	Outcome Employ specialist knowledge of rare disease genomic testing to deliver a safe and high-quality service.
# 8	Outcome Demonstrate appropriate communication skills with healthcare professional colleagues to inform the clinical management of patients referred for rare disease genomic testing.